Would you use PCC for clotting factor repletion in acute life threatening hemorrhage in a patient with elevated INR from coagulopathy of liver disease?

I do not use KCentra in this clinical situation.

Firstly, the INR is validated for vitamin K antagonists (VKA) therapy only. The VKAs inhibit the synthesis of factors II, VII, IX, and X while the liver produces more clotting factors such as fibrinogen, II, V, VII, IX, X, XI, XII, etc. The INR has not been validated in coagulopathy of liver diseases. The INR does not predict bleeding tendency in patients with liver failure or systemic diseases (such as DIC).

Secondly, KCentra contains clotting factors II, VII, IX, X only. In liver failure, many more clotting factors are reduced. KCentra does not replace factors V, XI, etc. If I want to replace clotting factors in liver failure-induced coagulopathy, I'd use FFP and cryoprecipitates (cryoprec...

I do not routinely use KCentra for clotting factor repletion in patients with life-threatening hemorrhage due to coagulopathy of liver disease. KCentra (or prothrombin complex concentrate) is FDA approved for urgent reversal of coagulation factor deficiency induced by vitamin K antagonists, and there is little evidence that it is helpful in the setting of coagulopathy of liver disease.

In addition to IV vitamin K repletion (e.g. 10mg IV daily x3 days), antifibrinolytics such as aminocaproic acid/tranexamic acid are extremely useful here. Patients with liver disease often have elevated plasma tPA levels, due to decreased hepatic clearance + increased endothelial production, and an Amicar/TXA bolus followed by drip can quickly temporize bleedi...